# Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks

> **NCT07310290** · — · RECRUITING · sponsor: **AbbVie** · enrollment: 189 (estimated)

## Conditions studied

- Migraine

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07310290
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 189 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07310290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07310290, "Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07310290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*